Related Experiment Video
Updated: May 9, 2026

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
Published on: February 11, 2019
Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development
C Dutruel1, F Bergmann2, I Rooman3
1Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is usually incurable. Contrary to genetic mechanisms involved in PDAC pathogenesis, epigenetic alterations are ill defined. Here, we determine the contribution of epigenetically silenced genes to the development of PDAC. We analyzed enriched, highly methylated DNAs from PDACs, chronic pancreatitis (CP) and normal tissues using CpG island microarrays and identified WNK2 as a prominent candidate tumor suppressor gene being downregulated early in PDAC development. WNK2 was further investigated in tissue microarrays, methylation analysis of early pancreatic intraepithelial neoplasia (PanIN), mouse models for PDAC and pancreatitis, re-expression studies after demethylation, and cell growth assays using WNK2 overexpression. Demethylation assays confirmed the link between methylation and expression. WNK2 hypermethylation was higher in tumor than in surrounding inflamed tissues and was observed in PanIN lesions as well as in a PDAC mouse model. WNK2 mRNA and protein expressions were lower in PDAC and CP compared with normal tissues both in patients and mouse models. Overexpression of WNK2 led to reduced cell growth, and WNK2 expression in tissues correlated negatively with pERK1/2 expression, a downstream target of WNK2 responsible for cell proliferation. Downregulation of WNK2 by promoter hypermethylation occurs early in PDAC pathogenesis and may support tumor cell growth via the ERK-MAPK pathway.
Insights
Epigenetic silencing of the WNK2 gene through hypermethylation is an early event in pancreatic cancer development. This downregulation promotes tumor growth by affecting the ERK-MAPK pathway.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with poorly understood epigenetic mechanisms.
- Genetic alterations are well-studied, but the role of epigenetic silencing in PDAC pathogenesis remains unclear.
Purpose of the Study:
- To investigate the contribution of epigenetically silenced genes to PDAC development.
- To identify specific genes downregulated early in PDAC due to epigenetic alterations.
Main Methods:
- Analysis of highly methylated DNA from PDAC, chronic pancreatitis (CP), and normal tissues using CpG island microarrays.
- Investigation of WNK2 in tissue microarrays, methylation analysis of pancreatic intraepithelial neoplasia (PanIN), and PDAC mouse models.
- Re-expression studies after demethylation and cell growth assays with WNK2 overexpression.
Main Results:
- WNK2 was identified as a tumor suppressor gene downregulated early in PDAC development.
- WNK2 hypermethylation was observed in PDAC, CP, PanIN lesions, and a PDAC mouse model.
- WNK2 downregulation correlated with reduced cell growth and negatively with pERK1/2 expression, suggesting involvement in the ERK-MAPK pathway.
Conclusions:
- WNK2 promoter hypermethylation is an early event in PDAC pathogenesis.
- Downregulation of WNK2 contributes to tumor cell proliferation, potentially via the ERK-MAPK pathway.
Related Concept Videos
Canonical Wnt Signaling Pathway
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Non-Canonical Wnt Signaling Pathways
PI3K/mTOR/AKT Signaling Pathway

